Clinical Studies
TherMatrx® Office Thermo Therapy™ is an advanced thermo therapy for benign prostatic hyperplasia (BPH) designed for in-office use.1 Proven safe and effective, this minimally invasive treatment requires only mild oral medications. 1
Proven Safe
In the TherMatrx PMA clinical study, no long-lasting side effects or adverse events were reported. Post treatment side effects like bladder spasms or hematuria were generally transitory, minor and self resolving. In addition, there was less than 1% decrease in sexual function. 1, 2
| Rate of Incidence | |
|---|---|
| Rate of Incidence | |
| Rectal damage/fistual 1 | 0.0% |
| Retrograde ejaculation 1 | 0.0% |
| Painful or difficult ejaculation 1 | 0.0% |
| Loss of ejaculate or decreased fluid volume 1 | 0.0% |
Exceptional Patient Tolerance
Only mild oral medications are needed for excellent patient tolerance and comfort during treatment. 1 The following is an example of typical medications prescribed by physicians.
- Ativan® 1-2 mg (PO)4
- Toradol® 10 mg (PO)4
- Levsin® 0.5 mg (SL)
- Cipro® 500 mg (PO)
No narcotics, IV sedation or prostatic block are recommended.
Proven Effective
In the clinical study, the American Urology Association (AUA) symptom score and peak flow rate both showed statistically significant improvement after treatment with TherMatrx® Office Thermo Therapy™. 1
Clinical Studies
Click here for a bibliography of Peer Reviewed Journal Articles and Abstracts.
Ativan is a registered trademark of Wyeth Laboratories. Cipro is a registered trademark of Bayer Corporation. Levsin is a registered trademark of Schwarz Pharma. Toradol is a registered trademark of Roche Laboratories.
1. Transurethral Microwave Thermotherapy System. TherMatrx TMx-2000™. PMA P000043 summary of safety and effectiveness data. Approved June 29, 2001. Available at: www.fda.gov/cdrh/pdf/p000043.html.
2. Tepera C, Albala D, Andriole G, Davis BE, Kabalin JN, Lingeman, Nuzzarello J, Eure GR. Transurethral microwave thermotherapy (TUMT) using the TherMatrx TMX-2000. Improved sexual function exhibited in a randomized, blinded study comparing TUMT with a sham procedure in patients with benign prostatic hyperplasia (BPH). 52nd Annual James C. Kimbrough Urological Seminar Jan 26-21, 2005. Honolulu, Hawaii.
4. Albala D, Nuzzarello J, Kabalin JN, Andriole GL, Eure GR, Davis BE, Lingeman JE. Transurethral microwave thermotherapy (TUMT) using the TherMatrx TMX-2000ª: a quantitative assessment of patient tolerance. J Urol Apr 2002;167(4 suppl.):296 abstract 1165.